What does Vaxess do?
Vaxess is a biotechnology company that develops a proprietary microarray patch technology paired with a specialized applicator. This platform leverages advanced biomaterials that enable precise dose control and versatile payload delivery without the need for refrigeration.
How much did they raise?
The company raised $9M in a funding round with RA Capital Management and Engine Ventures acting as lead investors. Although the round is classified as unknown, the substantial capital will support further product development and manufacturing scale-up.
What are their plans for the money?
Vaxess plans to use the funding to further its work in GLP-1 and to expand manufacturing capabilities. This investment is expected to bolster their lead program, foster new partnerships for additional therapeutics, and potentially transform access to stable, temperature-resilient treatments in low-resource settings.
What have they achieved so far?
Vaxess has made notable progress with its platform, demonstrating innovative microarray patch technology that provides controlled dose delivery and adapting its biomaterials for varied therapeutic needs, which positions it well for future clinical and market advancements.
